Verve stock price currently consolidates after a sharp

Verve stock price currently consolidates after a sharp 5% move earlier this month. Chart patterns show possible accumulation by long-term funds, especially given competitive developments in cardiovascular gene therapy. Despite these upgrades,the analysts have not made any major changes to their price target of US$31.00, implying that their latest estimates don't have a long term impact on what they think the stock is worth. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic Verve Therapeutics analyst has a price target of US$55.00 per share, while the most pessimistic values it at US$15.00. So we wouldn't be assigning too much credibility to analyst price targets in this case, because there are clearly some widely different views on what kind of performance this business can generate. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business. Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023, after Eli Lilly and Co on Wednesday said it will cut list prices by 70% for its most commonly prescribed insulin products, Humalog and Humulin, beginning from the fourth quarter of this year. REUTERS/Mike Blake/File Photo Purchase Licensing Rights , opens new tab Price action in Verve stock indicates possible upward drift, especially if institutional investors continue increasing their stake — a trend supported by last week's Form 13F filings.